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Abstract
Carvedilol is a non-selective b-blocker indicated in the treatment of hypertension and heart failure. Although the differential
pharmacological effects of individual Carvedilol enantiomer is supported by preceding studies, the cellular response to each
enantiomer is not well understood. Here we report the use of GC-MS metabolomic profiling to study the effects of Carvedilol
enantiomers on vascular smooth muscle cells (A7r5) and to shed new light on molecular events underlying Carvedilol treatment. The
metabolic analysis revealed alternations in the levels of 8 intracellular metabolites and 5 secreted metabolites in A7r5 cells incubated
separately with S-a n dR-Carvedilol. Principal component analysis of the metabolite data demonstrated the characteristic metabolic
signatures in S-a n dR-Carvedilol-treated cells. A panel of metabolites, including L-serine, L-threonine, 5-oxoproline, myristic acid,
palmitic acid and inositol are closely correlated to the vascular smooth muscle contraction. Our findings reveal the differentiating
metabolites for A7r5 cells incubated with individual enantiomer of Carvedilol, which opens new perspectives to employ metabolic
profiling platform to study chiral drug-cell interactions and aid their incorporation into future improvement of b-blocker therapy.
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Introduction
b-blockers, also known as b-adrenergic receptor antagonists, are
a class of drugs that block catecholamines by binding to b-
adrenergic receptors. There are three known types of b-adrenergic
receptors, designated b1 (located manly in heart and kidneys), b2
(located mainly in lungs, uterus, liver, gastrointestinal tract,
vascular smooth muscle and skeletal muscle) and b3 (located in
fat cells). The b-adrenergic receptors are a class of G-protein-
coupled receptors characterized by seven transmembrane span-
ning domains forming a pocket in which agonists and antagonists
compete for their binding sites [1]. Carvedilol, a nonselective b-
antagonist (b1, b2), has proven potent antihypertensive activity and
also effective in the treatment of coronary artery disease and
congestive heart failure [2]. It also possesses calcium channel
blocking effect by inhibiting voltage-dependent L-type Ca
2+ in
vascular smooth muscle cells [3]. Carvedilol has an asymmetric
carbon atom, which gives rise to S- and R-enantiomers. The
racemic mixture of Carvedilol is administered clinically although it
results predominantly from S-Carvedilol [4,5]. Although each
enantiomer exhibits differential pharmacological effects, the
cellular response to individual enantiomer is not well understood.
Since the metabolite concentrations represent sensitive responses
of cells to external stimuli [6,7], the analysis of metabolic profiling
of A7r5 cells underlying Carvedilol enantiomers treatment will
greatly facilitate the understanding on Carvedilol-cell interactions.
We have previously developed LC-MS/MS-based proteomics
system to study the cellular responses to the treatments by different
generations of beta-blockers [8,9,10]. Our study identified several
differentially expressed proteins mediating the vascular smooth muscle
contraction and also highlighted the differences associated with the
treatment of individual enantiomer. While proteomics data has
provided important insights into the active effects of S-enantiomers,
metabolomics may shed new light on the understanding of drug-cell
interactions as it reveals the downstream changes of proteome.
Recent advances of instrumentation and computation has
enabled the simultaneous analysis of a large number of
metabolites. Gas chromatography coupled with mass spectrometry
(GC-MS) has proven to be an effective combination for
metabolites identifications and quantifications in mammalian cell
lines [11,12,13,14] due to its excellent resolution and sensitivity.
The aim of the current study was to obtain a systematic view of
the cellular responses to Carvedilol enantiomers. We wished to
identify multiple metabolites that could facilitate the understand-
ing of the in vitro actions of Carvedilol and aid their incorporation
into future improvement of b-blocker therapy. In this study, we
employed GC-MS-based metabolomic profiling system to func-
tionally assign Carvedilol enantiomers induced changes in the
metabolism of A7r5 cells. This study identifies the differential
effects of Carvedilol enantiomers on both intracellular and
secreted metabolites including those involved in the vascular
smooth muscle contraction pathway. Our results support the fact
that S-Carvedilol possesses more biological activity. Moreover, our
study demonstrates the feasibility of GC-MS-based metabolic
profiling as an analytical tool to understand drug-cell interactions.
Results
GC-MS profiles depict the intracellular response of A7r5
cells to S- and R-Carvedilol
We performed GC-MS-based metabolomic profiling in A7r5
cells incubated with individual enantiomer of Carvedilol. A total of
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e1544132 intracellular metabolites were identified using the NIST library
and SHIMADZU GC/MS Metabolite Mass Spectra Database
with similarity index above 90%. Out of the 32 metabolites, 8
displayed significantly different levels (p,0.05) in A7r5 cells
incubated with S-Carvedilol, while the changes of most metabo-
lites in R-Carvedilol-treated cells are less significant relative to
control cells (Figure 1). For example, the levels of palmitic acid and
myristic acid displayed up-regulated in S-Carvedilol-treated cells
while the changes in R-Carvedilol-treated cells is not significant
compared with control cells.
Multivariate statistical modeling using principal component
analysis (PCA) was performed on the GC-MS spectra of four
independently grown replicates. PCA has been successfully applied
to build classification models from metabolomics data
[15,16,17,18]. The scores plot (Figure 2a) resulting from PCA
revealed clear discrimination between the intracellular metabo-
lome of A7r5 cells incubated with S- and R-Carvedilol, indicating
that A7r5 cells displayed distinctly metabolic characteristics under
individual Carvedilol enantiomer treatment. It was also found out
that L-serine, palmitic acid and myristic acid contributed more
significantly to distinguishing A7r5 cells incubated with S-o rR-
Carvedilol after loadings plot analysis (Figure 2b).
GC-MS profiles depict the secreted metabolome of A7r5
cells in response to the treatment of S- and R-Carvedilol
The secreted metabolites in culture medium from A7r5 cells
were analysed using GC-MS system. Analysis detected 9 secreted
metabolites. A representive GC-MS total ion chromatograms is
shown in Figure 3 and the up-regulated metabolite L-Alanine was
observed in S-Carvedilol-treated cells. The culture medium
incubated at the same conditions was set as negative control.
From four independent exepriments, 4 metabolites were indenti-
fied as significantly changes between samples incubated with S-
Carevdilol and control, while the changes in R-Carevdilol-treated
cells is less significant (Figure 4). PCA was performed on the GC-
MS spectra of four biological replicates from A7r5 cells incubated
with control, S- and R-Carvedilol. The PCA scores plot shown in
Figure 5a demonstrates that exposure of A7r5 cells to S-o rR-
Carvedilol caused distinct changes in the metabolome. Loadings
plot identified L-alanine, L-leucine, L-valine and succinic acid as
the major discriminators between S- and R-Carvedilol-treated cells
(Figure 5b).
Intracellular Calcium concentration variations in response
to Carvedilol enantiomers treatment
To investigate the calcium inhibition effect of each Carvedilol
enantiomer, the intracellular Ca
2+ concentration was measured.
The results indicated that the intracellular concentration in S-
Carvedilol-treated A7r5 cells was lower than that in control cells
(S:C, 0.84860.018, p,0.05), while the variations were less
significant in R-Carvedilol-treated cells (R:C, 0.93560.012,
p,0.05). Student’s t-test was performed to assess the significance
of the variance.
Discussion
In pharmacology, the importance of drug chirality and its role in
explaining the dramatic differences of individual enantiomers in
biological activities is increasingly appreciated [19]. Our previous
studies investigated the intracellular proteome in A7r5 cells incubated
with individual enantiomers of b-blockers and identified differentially
expressed proteins mediating the vascular smooth muscle contraction
[8,9,10]. In the current study, we have applied GC-MS-based
metabolomicprofilingapproachto investigatethe cellularresponseto
the treatment of Carvedilol enantiomers. We wished to investigate
whether a metabolomic approach could identify signatures associated
with S-a n dR-Carvedilol treatment and whether these signatures
could shed new light into the in vitro actions of Carvedilol. To our
knowledge, this is the first study to apply a metabolic profiling system
to characterize chiral drug-cell interactions. The GC-MS-based
metabolic profiling platform paired with multivariate statistical
Figure 1. Differential expression levels of intracellular metabolites in S- and R-Carvedilol-treated cells. The ‘‘asterisk’’ indicated the
statistical significance of the metabolite changes by Student’s t-test: *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0015441.g001
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PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e15441Figure 2. Principal component analysis (PCA) of the GC-MS spectra from intracellular metabolites in A7r5 cells. A) PCA scores plot.
Solvent control (red), S-Carvedilol (blue) and R-Carvedilol (green) are included. B) PCA loading plot.
doi:10.1371/journal.pone.0015441.g002
Carvedilol Induced Metabolomic Profiling
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e15441method (PCA) has enabled us to highlight the distinct cellular
response to individual enantiomers of Carvedilol and several
metabolites altered in the treatment of S-Carvedilol.
To obtain the information about the metabolic variations
underlying the treatment of Carvedilol enantiomers, we first
analysed the intracellular metabolome in A7r5 cells. From four
independent experiments, 8 metabolites were consistently identi-
fied with statistically significant changes and closely relevant with
the cell functions associated with the treatment of S-Carvedilol and
will be discussed as follows.
The intracellular Ca
2+ has been a central player in regulating
vascular smooth muscle contraction and relaxation [20,21,22,23].
A decreased of intracellular Ca
2+ concentration will elicit rela-
xation. The previous study has suggested that Carvedilol exhibited
the inhibitory effects on Ca
2+ mobilization and this unique action
may contribute to its antihypertensive effect [3]. Using KEGG
database and literature mining, we have linked the intracellular
metabolic variations to the vascular smooth muscle relaxation
pathway (Figure 6). Changes in amino acid levels were variable. L-
serine, a precursor of central neurotransmitters, was found to be
up-regulated in cells incubated with S-Carvedilol compared with
control cells and those incubated with R-Carvedilol. The up-
regulated L-Serine has been reported to exhibit antihypertensive
effect by evoking vasodilatation in vascular smooth muscles cells
[24]. The vasodilatation effect is mediated by activating Ca
2+-
activated K
+ channel [25], which induces the hyperpolarization in
vascular smooth muscle cells and promotes the closure of voltage-
operaetd calcium channels (VOC). The inactiviated vascular
Figure 3. The representive GC-MS spectra of L-Alanine derived from total ion chromatograms. Culture medium (black), untreated cells
(red), R-Carvedilol-treated cells (green) and S-Carevdilol-treated cells (blue).
doi:10.1371/journal.pone.0015441.g003
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2+ influx, which results in the
Ca
2+ reduction and subsequent relaxation or vasodilatation. In
contrast, levels of L-threonine and 5-oxoproline were reduced in S-
Carvedilol-treated cells. L-threonine is an essential amino acid that
could be used for serine biosynthesis [26]. 5-oxoproline is
converted into glutamate by 5-oxoprolinase [27]. Glutamate
activates glutamate receptor that inhibits calcium channel, which
induces muscle relaxation. Despite great effort, we were not able to
identify glutamate in this study.
The fatty acids level treaded toward increase in cells incubated
with S-Carvedilol. The up-regulated myristic acid and palmitic acid
have been reported to stimulate nitric-oxide Synthase, which in turn
actives the production of nitric oxide (NO) [28]. In the cardiovascular
system, NO plays an essential role in hemodynamics and controlling
vascular remodeling [29,30,31]. For example, in vascular smooth
muscles cells NO stimulates soluble guanylyl cyclase (s-GC) to
generate the second messenger cGMP, which results in activation of
cGMP-dependent protein kinase G (PKG) [32,33]. Inositol trispho-
sphate receptor (IP3R) is a membrane glycoprotein complex acting as
Ca
2+ release channel activated by the second messenger inositol
trisphosphate (IP3). The activated PKG is recruited by the IP3R-
associated cGMP kinase substrate (IRAG), resulting in IP3R
phosphorylation and inhibition of Ca
2+ release from endoplasmic
reticulum (ER) [34]. The reduced Ca
2+ concentration in vascular
smooth muscle cells induced by increased NO production thus results
in muscle relaxation. The Ca
2+ concentration measurement assay
was conducted to prove our hypothesis and the results indicated that
the Ca
2+ concentration in S-Carvedilol-treated cells is down-
regulated compared with control cells and those incubated with R-
Carvedilol. In addition, our observation of a decreased level of
inositol in cells incubated with S-Carvedilol may be due to the
decrease of IP3 caused by the phosphorylation of IP3R.
Lactic acid, an end product of glycolysis, was up-regulated in cells
incubated with S-Carvedilol. A higher concentration of lactic acid is
produced in vascular smooth muscle cells when faced with low levels
of oxygen. Intaking of Carvedilol may cause some common side
effects in clinic such as shortness of breath, dizziness [35,36]. Our
observation of increased level of lactic acid could be related with the
side effects induced by S-Carvedilol. Glycolic acid is the smallest a-
hydroxy acid which is able to exfoliate dead skin cells and encourage
cell regeneration. The function of glycolic acid in vascular smooth
muscle cells in unclear. The increased glycolic acid could be possibly
involved in the inhibition of vascular smooth muscle thickening that
spontaneously happens in hypertensive rats [37].
Metabolites secretion by a cell reflects the biochemical response
to external stimuli. We have previously investigated the secreted
proteome in A7r5 cells incubated with b-blockers and a common
secreted protein T-kininogen was identified as a potential drug
marker [38,39]. Since the metabolites are the end products of
cellular regulatory processes, the quantitative analysis of the
secreted metabolites in A7r5 cells upon Carvedilol enantiomers
treatment should provide us a complementary understanding on
overall cellular response. A panel of 4 metabolites (L-alanine, L-
leucine, L-valine, succinic acid) showed up-regulated in cells
incubated with S-Carvedilol compared with control cells and those
incubated with R-Carvedilol. L-leucine and L-valine are essential
amino acids with three branched-chains, which could be used as
an energy source by muscle tissue. L-alanine can be produced
from branched chain amino acids, such as L-leucine and L-valine.
The possible reason that the high secreted levels of these amino
acids is to keep them in balance in the more relaxed cells. PCA
analysis demonstrates the characteristic signatures of cells
incubated with individual enantiomers of Carvedilol. Succinic
acid secretion was strongly enhanced with S-Carvedilol treatment,
which may result from the inactivation of succinate dehydroge-
nase. The highly produced NO in S-Carvedilol-treated cells may
selectively inhibit succinate dehydrogenase activity [40]. Since the
secreted metabolites variations in a cell reflect its internal
metabolic state, the distinct secretion profiles further confirm the
differences of intracellular metabolome of A7r5 cells in response to
the S- and R-Carvedilol treatment. However, no specific
production or secretion pathways were found to connect secreted
metabolic variations to the changes in intracellular metabolic
states due to the limited secreted metabolites seen. The possible
explanations for this: 1) Metabolites are very instable and
degraded rapidly in culture medium. 2) Partial of the secreted
metabolites may not be amenable to derivatization for GC-MS
analysis. The complementary analytical technologies (for example,
LC-MS, NMR) without such derivatization may become alterna-
tive ways to investigate the secreted metabolome in A7r5 cells.
This should be dressed in our further study.
In conclusion, our results highlight the potential of GC-MS-
based metabolic profiling of A7r5 cells in response to Carvedilol
enantiomers treatment. The cells incubated with individual
enantiomers demonstrate characteristic metabolic signatures,
which is consistant with the fact that each enantiomer exhibits
differential biological activities. Specifically, the metabolic changes
observed in A7r5 cells in response to S-Carvedilol treatment were
Figure 4. Differential expression levels of secreted metabolites in S- and R-Carvedilol-treated cells. The ‘‘asterisk’’ indicated the
statistical significance of the metabolite changes by Student’s t-test: *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0015441.g004
Carvedilol Induced Metabolomic Profiling
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15441closely involved in the vascular smooth muscle relaxation pathway.
These findings enhance our understanding of Carvedilol-cell
interactions, which may in turn aid their incorporation into future
improvement of b-blocker therapy.
Materials and Methods
GC-MS sample preparation
Vascular smooth muscle cell line (A7r5) was obtained from
American Type Culture Collection (ATCC) and cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 U/mL
streptomycin (Life Technologies). Cells were maintained at 37uCi na n
atmosphere of 5% CO2 with the medium replaced every 24 hours.
1.5610
7 cells were treated with either S-o rR-Carvedilol at a
concentration of 5 mM due to MTT reduction analysis [10]. Cells
treatedinparallelwithequal amountsofdimethylsulfoxide(DMSO)
were used as control. After 48 hours, culture medium was collected,
filtered through a 0.2 mm filter (WHATMAN), and immediately
frozen in liquid nitrogen. Cells were washed with cold PBS twice,
harvested and snapped frozen in liquid nitrogen. Carvedilol
enantiomers were previously separated from their racemic form
using HighPerformanceLiquidChromatography(HPLC)inourlab
[10]. Four independent experiments were conducted.
Figure 5. Principal component analysis (PCA) of the GC-MS spectra from secreted metabolites in A7r5 cells. A) PCA scores plot. Solvent
control (red), S-Carvedilol (blue) and R-Carvedilol (green) are included. B) PCA loading plot.
doi:10.1371/journal.pone.0015441.g005
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performed using a modified Mainak Mal [41] and Hindrik Mulder
[11] procedure. Cell pellets were dissolved in a mixture of
chloroform/methanol/water in ratio of 2:5:2 (v/v/v). Ribitol
(2 mg/mL dissolved in water, 10 mL) was added into the
extraction solvent as internal standard to correct for metabolites
losses during sample preparation. The samples were ultra-
sonicated in an ice bath ultra-sonicator for 30 min and
subsequently centrifuged at 18000 g for 10 mins at 4uC. 0.8 mL
supernatant was collected and evaporated to complete dryness
overnight using a TurboVapH LV Concentration Workstation.
The culture medium samples were prepared by spiking 500 mLo f
each culture medium with 10 mL internal standard solution
(ribitol, 2 mg/mL dissolved in water) and lyophilised. Immediately
prior to GC-MS analysis, derivatization was performed in two
steps: Firstly, methoximation was carried out by dissolving the
sample in 50 mL of 20 mg/mL solution of methoxyamine
hydrochloride in pyridine to protect the carbonyls. The incubation
was kept at 37uC for 60 min. Silylation was then carried out by
adding 100 mL of N-methyl-N-(trimethylsilyl)-trifluoroacetamide
(MSTFA) with 1% trimethylchlorosilane (TMCS) to each sample
for 30 min at 70uC. After incubation, samples were shaken for
2 hours at room temperature and then transferred to vials for GC-
MS analysis.
GC-MS analysis
All samples were analysed using a Shimadzu QP2010Plus GC-
MS system (Shimadzu, Kyoto, Japan) equipped with a DB-5
fused-silica capillary column (30 m6250 mm i.d.; film thickness:
0.25 mm; Agilent J&W Scientific, Folsom, CA, USA). Each 1 mL
of the derivatised samples was injected into GC-MS system by
Shimadzu AOC-20i+s auto-sampler in the splitless mode. The
solvent cutoff time was set at 3.5 min. Helium was used as carrier
gas at 1.1 mL/min. The injection and ion source temperatures
were kept at 280 and 200uC, respectively. The oven temperature
was kept at 100uC for 4 min and increased at 4uC/min to 320uC
where it remained for 1.56 min. Detection was implemented in
electron impact (EI) ionization mode at 70eV. Mass spectra were
recorded from 35 to 600m/z with a scan time of 0.3 s.
Chromatogram acquisition and mass spectra identification were
processed using the Shimadzu GCMSsolution (version 2.5)
software. To allow normalization of retention times, a retention
index (RI) solution (C-10 to C-40) was injected into the GC-MS
system and performed by AART (Automatic Adjustment of
Retention Time) function of GCMSsolution software. All
chromatograms were subjected to noise reduction and baseline
correction prior to peak area integration. Chromatographic peak
deconvolution was performed using the following parameters:
peaks width=2 s, smoothing=3. For those peaks detected, the
peak area was calculated and normalized using the internal
standard generating a response ratio. Chemical identification of
detected metabolite peaks was preformed by searching NIST mass
spectral library and SHIMADZU GC-MS Metabolite Mass
Spectra Database (Release 1.0). Identification was regarded as
preliminary for spectra matched in the NIST library with a
similarity above 90%. Identifications were regarded as definitive if
the mass spectrum and retention index matched those of a
metabolite present in the SHIMADZU GC-MS Metabolite Mass
Spectra Database, which was prepared by analysis of authentic
chemical standards on the instrument employed in this study. All




2+ concentration was measured using a
Fluo-4 NW Calcium Assay Kit (Invitrogen, Eugene, OR, USA)
according to the manufacturer’s protocol. Briefly, each type of
A7r5 cells was incubated at 37uC for 30 min in the Fluo-4 dye
solution dissolved in assay buffer (Component C, Invitrogen) in a
96-well plate. Following incubation, cells were equilibrated at
room temperature for an additional 30 min. The assay was
performed using a fluorometer (Tecan) at 494 nm for excitation
and 516 nm for emission.
Statistical analysis
The significance of intracellular and secreted metabolite level
changes from A7r5 cells in response to Carvedilol enantiomers
treatment was calculated using the Student’s t-test, where all
detected metabolites were tested and a threshold of p,0.05 was
used all this study. Principle component analysis (PCA) was
performed to determine whether intracellular and secreted
patterns of metabolite changes in A7r5 cells under treatment of
S- and R-Carvedilol, in addition to the altered levels of individual
metabolites. PCA analysis is an unsupervised clustering method
aiming at summarizing data with reduced dimensions. In this
study, four biological replicates were used to perform PCA analysis
Figure 6. Schematic representation of the vascular smooth muscle relaxation pathway showing the most relevant metabolic
changes inudced by S-Carvedilol. Metabolites in red/green display increased/decreased concentrations upon S-Carvedilol treatment.
doi:10.1371/journal.pone.0015441.g006
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Sweden) software.
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